GRACEcast

By Howard (Jack) West, MD

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Edu... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.

GRACEcast episodes:

June 15, 2013 Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.
...more
2min
June 15, 2013 Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
...more
13min
June 13, 2013 Do you need Avastin in first line and maintenance therapy in advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
...more
7min
June 12, 2013 Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
...more
2min
June 12, 2013 Can we predict which patients will benefit from Tarceva based on a blood test?
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
...more
8min
June 11, 2013 Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?
Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.
...more
2min
June 10, 2013 Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).
...more
6min
June 09, 2013 Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (video)
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
...more
22min
June 09, 2013 Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
...more
22min
June 07, 2013 Is it possible to test for biomarkers in lung cancer on a national scale?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).
...more
6min

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.